Physician profile
Vidhya Subramanian
NPI 1295752004
$12,920.63
in general payments reported to CMS, 2019-2025
47 companies · $4,842 in 2025
The $4,842 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $226 · 2021: $71.93 · 2022: $576 · 2023: $3,220 · 2024: $3,426 · 2025: $4,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Gift: $59.40 · Education: $39.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,388.86 |
| Gift | $59.40 |
| Education | $39.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,348.16 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,244.75 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,075.50 | 2020-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $680.26 | 2023-2025 | Afrezza |
| Insulet Corporation | $600.69 | 2024-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $586.28 | 2019-2025 | |
| Dexcom, INC. | $574.11 | 2023-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $518.27 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $500.14 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $443.83 | 2023-2025 | |
| Corcept Therapeutics | $428.02 | 2024-2025 | Korlym |
| Abbvie INC. | $420.66 | 2023-2025 | Synthroid |
| Tandem Diabetes Care, INC. | $418.02 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $373.04 | 2022-2025 | Jardiance, Synjardy |
| Alexion Pharmaceuticals, INC. | $350.49 | 2022-2025 | Strensiq |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $349.35 | 2022-2025 | Unithroid |
| Avvisto Therapeutics, LLC | $293.28 | 2025 | Cycloset |
| Ascendis Pharma Endocrinology INC | $270.15 | 2023-2025 | Yorvipath |
| Antares Pharma, INC. | $265.78 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Embecta Corp. | $213.77 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Beta Bionics, INC. | $212.14 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $183.50 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $165.30 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $147.71 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $140.21 | 2023 | Minimed 780g, Intellis Adaptivestim |
| Madrigal Pharmaceuticals | $117.73 | 2024-2025 | Resmetirom, Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.62 | 2023-2024 | Cycloset |
| Acella Pharmaceuticals, LLC | $73.65 | 2024-2025 | NP Thyroid 60 |
| Tolmar, INC. | $68.09 | 2023-2025 | Jatenzo |
| Ibsa Pharma INC. | $67.27 | 2023-2025 | Flector, Licart, Tirosint |
| Novartis Pharmaceuticals Corporation | $63.71 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $61.71 | 2025 | |
| Verity Pharmaceuticals INC. | $57.00 | 2024-2025 | Tlando |
| Horizon Therapeutics Plc | $55.71 | 2022-2023 | Tepezza |
| Ascensia Diabetes Care US INC. | $55.06 | 2024-2025 | |
| Kyowa Kirin, INC. | $53.16 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $52.05 | 2025 | Twiist |
| Echosens North America, INC. | $45.54 | 2025 | Fibroscan |
| Esperion Therapeutics, INC. | $41.63 | 2023-2024 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $34.13 | 2024 | Crysvita |
| Currax Pharmaceuticals LLC | $33.45 | 2021-2025 | Contrave |
| Averitas Pharma INC. | $29.69 | 2023 | Qutenza |
| Alvogen INC | $25.95 | 2025 | Teriparatide |
| Evoke Pharma, INC. | $21.64 | 2025 | |
| Recordati_rare_diseases_inc. | $20.25 | 2023 | Signifor Lar, Isturisa |
| Aimmune Therapeutics, INC. | $17.90 | 2025 | Zenpep |
| Halozyme INC | $17.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Subramanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.